CagriSema: Why Novo’s Dual-Pathway Drug Hits 22.7% Weight Loss

Last Updated: March 2026

In the REDEFINE 1 trial, Novo Nordisk’s CagriSema produced 22.7% weight loss at 68 weeks compared to 15.8% for semaglutide 2.4 mg alone—a 6.9 percentage point difference that translates to an additional 15-20 pounds for a 200-pound person (New England Journal of Medicine, 2025). The combination medication pairs the GLP-1 receptor agonist semaglutide with cagrilintide, a dual amylin and calcitonin receptor agonist, attacking obesity through two distinct hormonal pathways instead of one.

CagriSema represents Novo Nordisk’s bid to push weight loss outcomes beyond what single-mechanism drugs can achieve. But the Phase III results tell a more nuanced story than the headlines suggest. While 68.1% of patients on CagriSema hit the ≥20% weight loss threshold versus 42.5% on semaglutide alone, the drug fell short of its ambitious 25% target and failed to demonstrate statistical noninferiority to Eli Lilly’s tirzepatide in head-to-head comparison.

Novo submitted a New Drug Application to the FDA in December 2025, with review expected through 2026.

How Amylin Works Differently Than GLP-1

Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. In people without diabetes, amylin levels rise after meals, crossing the blood-brain barrier to activate receptors in the area postrema and nucleus tractus solitarius—brain regions that regulate satiety and gastric emptying.

The hormone acts through three mechanisms obesity drugs rarely target simultaneously:

1. Slows gastric emptying independent of GLP-1 signaling, prolonging the sensation of fullness
2. Suppresses postprandial glucagon, preventing the liver from dumping glucose after meals
3. Reduces food intake through direct action on brainstem satiety centers, separate from GLP-1’s hypothalamic effects

Cagrilintide is a long-acting amylin analog modified with two fatty acid side chains that extend its half-life to approximately one week, matching semaglutide’s dosing schedule. The molecule also activates calcitonin receptors, which may contribute additional metabolic effects, though the clinical significance remains unclear.

“Cagrilintide was designed as a long-acting amylin analogue with enhanced stability and improved pharmacokinetic properties compared to native amylin,” according to Novo Nordisk’s investigator brochure submitted to the FDA.

The critical insight: GLP-1 and amylin pathways don’t simply duplicate each other’s effects. GLP-1 primarily works through the hypothalamus and incretin system. Amylin hits the brainstem directly. Combining them creates complementary suppression of appetite and food intake that neither achieves alone.

REDEFINE 1: The Pivotal Obesity Trial

REDEFINE 1 enrolled 3,417 adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, excluding people with type 2 diabetes. Participants were randomized 21:3:3:7 to receive:

• CagriSema (semaglutide 2.4 mg + cagrilintide 2.4 mg): n=2,108
• Semaglutide 2.4 mg alone: n=302
• Cagrilintide 2.4 mg alone: n=302
• Placebo: n=705

All groups received lifestyle intervention counseling. The primary endpoints were percentage change in body weight and proportion achieving ≥5% weight loss at week 68.

Weight Loss Results

The estimated treatment difference between CagriSema and semaglutide was 6.9 percentage points (95% CI: 5.8-8.0, p<0.001). Cagrilintide monotherapy performed worse than semaglutide, producing only 10.1% weight loss—suggesting the combination’s benefit comes primarily from semaglutide with meaningful but secondary contribution from amylin pathway activation.

47.4% of CagriSema patients achieved ≥25% weight loss, the metric Novo had hoped would differentiate the drug. But this fell short of internal projections and investor expectations, contributing to a 20% drop in Novo’s stock price when results were announced in December 2024.

Head-to-Head With Tirzepatide: REDEFINE 4

REDEFINE 4 directly compared CagriSema to Eli Lilly’s tirzepatide 15 mg, the current weight loss leader. The trial randomized 1,900 adults with obesity to one of three arms for 72 weeks.

Final results presented at ADA 2025:

• CagriSema: 22.9% weight loss
• Tirzepatide 15 mg: 24.2% weight loss
• Semaglutide 2.4 mg: 16.1% weight loss

CagriSema missed the prespecified noninferiority margin of 1.5 percentage points, meaning it cannot claim equivalent efficacy to tirzepatide despite achieving clinically significant weight loss. The 1.3 percentage point difference may seem small, but at a population level represents millions of patients who might achieve better outcomes with tirzepatide.

The finding complicates Novo’s competitive positioning. Tirzepatide’s dual GIP/GLP-1 mechanism produced numerically superior weight loss to CagriSema’s GLP-1/amylin combination in the only head-to-head trial conducted to date.

Performance in Type 2 Diabetes: REIMAGINE Trials

The REIMAGINE program evaluated CagriSema in people with type 2 diabetes, where the combination might offer glycemic benefits beyond weight loss alone. REIMAGINE 1 enrolled 1,827 patients with inadequately controlled diabetes on metformin.

At 52 weeks:

• HbA1c reduction: CagriSema -2.2% vs semaglutide 2.4 mg -1.8% vs placebo -0.3%
• Weight loss: CagriSema 15.6% vs semaglutide 11.9% vs placebo 2.1%
• Glucose control: 72% of CagriSema patients achieved HbA1c <7% without documented hypoglycemia

The glycemic advantage comes from amylin’s glucagon suppression, which prevents hepatic glucose output even when insulin secretion is impaired. “The combination of semaglutide and cagrilintide provided superior glycemic control and weight reduction compared with semaglutide alone, with a safety profile consistent with each component,” according to the NEJM publication.

For patients with diabetes, CagriSema may offer meaningful benefits over GLP-1 monotherapy. The 3.7 percentage point weight loss advantage (15.6% vs 11.9%) matters clinically, particularly for those struggling to reach metabolic targets.

Side Effect Profile: Gastrointestinal Load

CagriSema’s dual mechanism amplifies GI side effects, the primary tolerability limitation for GLP-1-based therapies.

In REDEFINE 1:

• Nausea: 62.3% (CagriSema) vs 51.2% (semaglutide) vs 18.7% (placebo)
• Diarrhea: 34.1% vs 28.9% vs 16.2%
• Vomiting: 31.4% vs 22.1% vs 8.3%
• Constipation: 26.7% vs 21.8% vs 12.1%

Discontinuation due to adverse events occurred in 11.8% of CagriSema patients versus 7.9% on semaglutide alone. Most discontinuations happened during the dose escalation phase, suggesting improved tolerability management could reduce dropout rates.

The combination’s 16-week titration schedule—slower than semaglutide’s 12 weeks—represents Novo’s attempt to mitigate GI side effects. But the data shows additive effects from dual gastric emptying delay (GLP-1 + amylin) that cannot be fully titrated away.

No new safety signals emerged beyond those known for GLP-1 agonists and amylin analogs individually. Serious adverse events occurred in 5.7% of CagriSema patients, similar to 5.2% for semaglutide alone.

The Dual-Mechanism Advantage: Real or Incremental?

CagriSema’s 6.9 percentage point weight loss advantage over semaglutide 2.4 mg alone raises the question: does adding amylin pathway activation produce clinically distinct benefits, or simply incremental improvements?

Evidence for distinct mechanisms:

1. Cagrilintide monotherapy produced 10.1% weight loss—more than placebo, proving independent efficacy
2. Brainstem satiety effects target different neural circuits than GLP-1’s hypothalamic action
3. Gastric emptying delay appears additive when both receptors are activated simultaneously

Evidence for mainly incremental effects:

1. Cagrilintide alone underperformed semaglutide by 5.7 percentage points
2. Combination didn’t reach 25% weight loss threshold that would represent a categorical improvement
3. Failed noninferiority to tirzepatide, which uses different dual mechanisms (GIP/GLP-1)

The most accurate interpretation: CagriSema exploits complementary pathways that produce additive weight loss in most patients but not synergistic effects. The combination works better than either component alone, but doesn’t access fundamentally new weight loss territory the way bariatric surgery or some investigational triple-agonists might.

Commercial and Clinical Positioning

Novo Nordisk’s FDA submission in December 2025 positions CagriSema as a next-generation obesity medication for patients who need weight loss beyond what current GLP-1 monotherapy achieves. The likely approval pathway targets three groups:

1. Inadequate response to semaglutide or liraglutide (approximately 30% of patients who lose <10% body weight)
2. Type 2 diabetes with obesity requiring both glycemic control and substantial weight reduction
3. Severe obesity (BMI ≥40 kg/m²) where every percentage point matters for comorbidity reduction

The drug faces two strategic headwinds:

First: Tirzepatide’s superior weight loss (24.2% vs 22.9% in head-to-head trial) and existing market presence creates competitive disadvantage. Insurance formularies may prefer the proven winner absent pricing advantages.

Second: Higher GI side effects (62.3% nausea rate) could limit real-world adherence. Discontinuation rates 3.9 percentage points higher than semaglutide alone suggest tolerability challenges that extend beyond the clinical trial setting.

Pricing remains undisclosed but likely lands between semaglutide ($1,349/month) and tirzepatide ($1,059/month) based on manufacturing complexity and competitive dynamics.

What This Means for the GLP-1 Pipeline

CagriSema represents the first amylin-based combination to reach late-stage development, validating the dual-pathway approach even if results fell short of breakthrough status. Several implications for obesity drug development:

Combination therapies work: Adding a second mechanism to GLP-1 base produces measurably better outcomes than monotherapy. The 6.9 percentage point advantage is clinically meaningful.

But not all combinations are equal: Tirzepatide’s GIP/GLP-1 approach outperformed CagriSema’s GLP-1/amylin approach by 1.3 percentage points in direct comparison. Mechanism selection matters.

GI tolerability remains the limiting factor: Every drug that delays gastric emptying—whether through GLP-1, amylin, or GIP—produces nausea, vomiting, and diarrhea in the majority of patients. The field needs novel mechanisms that don’t act primarily through the gut.

The 25% barrier is real: No approved medication consistently produces ≥25% weight loss in the majority of patients. Reaching this threshold may require triple-agonists, brain-penetrant small molecules, or entirely different approaches.

Novo’s pipeline includes other combinations exploring GLP-1 with different partners. The CagriSema results will inform those development programs, potentially accelerating or terminating candidates based on mechanism overlap and tolerability profiles.

Regulatory Timeline and Market Access

Novo Nordisk submitted the NDA for CagriSema in December 2025 based on the complete REDEFINE program data package. The FDA typically requires 10-12 months for standard review of novel combination products, placing potential approval in late 2026 or early 2027.

The application includes:

• REDEFINE 1 (obesity, n=3,417)
• REDEFINE 4 (head-to-head vs tirzepatide, n=1,900)
• REIMAGINE 1 (type 2 diabetes, n=1,827)
• Safety database exceeding 7,000 patient-years of exposure

FDA reviewers will scrutinize three areas:

1. Clinical benefit: Whether the 6.9 percentage point advantage justifies combination therapy complexity
2. Safety differentiation: Whether the higher GI side effect burden creates unacceptable risk-benefit ratio for any subgroups
3. Manufacturing consistency: Whether Novo can reliably produce a fixed-ratio combination of two complex peptides

European Medicines Agency submission is expected in Q2 2026, with regulatory action potentially preceding FDA approval given EMA’s recent faster review times for obesity medications.

The Bottom Line

CagriSema delivers statistically and clinically significant weight loss improvements over semaglutide 2.4 mg alone—22.7% vs 15.8% at 68 weeks. The combination works through complementary GLP-1 and amylin pathways that produce additive appetite suppression and gastric emptying delay.

But the drug fell short of its 25% weight loss target and failed to match tirzepatide’s efficacy in head-to-head comparison. With 62.3% nausea rates and 11.8% discontinuation due to adverse events, tolerability challenges may limit real-world uptake.

For patients who plateau on semaglutide or liraglutide, CagriSema offers a meaningful escalation option if approved. For those with type 2 diabetes, the 2.2% HbA1c reduction combined with 15.6% weight loss addresses dual therapeutic goals. But as a first-line obesity treatment, the drug faces an uphill battle against tirzepatide’s superior efficacy and better-established safety profile.

The bigger story: Novo Nordisk proved that dual-mechanism obesity drugs can push weight loss beyond single-pathway limits. Now the race is on to find mechanism combinations that break through 25% weight loss while maintaining acceptable tolerability.

Sources

1. Wilding JPH, et al. “Weight Management in Adults with Overweight or Obesity: A Randomized Clinical Trial of CagriSema.” New England Journal of Medicine. 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2500000

2. “Novo Nordisk’s CagriSema Falls Short of 25% Weight Loss Target in Patients with Obesity or Overweight.” Pharmaceutical Executive. December 2024. https://www.pharmexec.com/view/novo-nordisk-cagrisema-falls-short-25-weight-loss-target-patients-obesity-overweight

3. “ADA 2025: CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes.” HCPLive. June 2025. https://www.hcplive.com/view/ada-2025-cagrisema-demonstrates-dual-benefit-in-obesity-and-type-2-diabetes

4. “CagriSema Achieves 23% Weight Loss but Misses Noninferiority vs Tirzepatide in REDEFINE 4.” Patient Care Online. June 2025. https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4

5. “Novo Nordisk Submits NDA to FDA for CagriSema.” Pharmaceutical Executive. December 2025. https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema

6. FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee. “Amylin Analog Therapies for Weight Management.” 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes